Moleculin Biotech Inc
Veridion Score
BETAMEDIUM CONF · 5/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is MBRX moving today?
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
MBRX overview
Related filings and maps
Congress activity in MBRX
No receipt-qualified Congressional disclosure is present for MBRX in the cached public ledger.
MBRX contract awards, year to date.
Public federal awards linked to this ticker.
MBRX lobbying filings, year to date.
Registered lobbying filings matched to Moleculin Biotech Inc.